211 related articles for article (PubMed ID: 19056767)
1. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver.
Moreno M; Ramalho LN; Sancho-Bru P; Ruiz-Ortega M; Ramalho F; Abraldes JG; Colmenero J; Dominguez M; Egido J; Arroyo V; Ginès P; Bataller R
Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G147-56. PubMed ID: 19056767
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress.
Briones AM; Rodríguez-Criado N; Hernanz R; García-Redondo AB; Rodrigues-Díez RR; Alonso MJ; Egido J; Ruiz-Ortega M; Salaices M
Hypertension; 2009 Jul; 54(1):142-9. PubMed ID: 19451411
[TBL] [Abstract][Full Text] [Related]
3. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats.
Klein S; Klösel J; Schierwagen R; Körner C; Granzow M; Huss S; Mazar IG; Weber S; van den Ven PF; Pieper-Fürst U; Fürst DO; Nattermann J; Lammert F; Sauerbruch T; Trebicka J
Lab Invest; 2012 Oct; 92(10):1440-50. PubMed ID: 22890553
[TBL] [Abstract][Full Text] [Related]
5. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver.
Bataller R; Gäbele E; Schoonhoven R; Morris T; Lehnert M; Yang L; Brenner DA; Rippe RA
Am J Physiol Gastrointest Liver Physiol; 2003 Sep; 285(3):G642-51. PubMed ID: 12773299
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells.
Trebicka J; Hennenberg M; Odenthal M; Shir K; Klein S; Granzow M; Vogt A; Dienes HP; Lammert F; Reichen J; Heller J; Sauerbruch T
J Hepatol; 2010 Oct; 53(4):702-12. PubMed ID: 20633948
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway.
Li J; Li JJ; He JG; Nan JL; Guo YL; Xiong CM
Cardiovasc Ther; 2010; 28(1):8-14. PubMed ID: 20074254
[TBL] [Abstract][Full Text] [Related]
8. Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity.
El-Moselhy MA; El-Sheikh AA
Biomed Pharmacother; 2014 Feb; 68(1):101-10. PubMed ID: 24268999
[TBL] [Abstract][Full Text] [Related]
9. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling.
Martin J; Denver R; Bailey M; Krum H
Clin Exp Pharmacol Physiol; 2005 Sep; 32(9):697-701. PubMed ID: 16173924
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts.
Shyu KG; Wang BW; Chen WJ; Kuan P; Hung CR
Eur J Heart Fail; 2010 Mar; 12(3):219-26. PubMed ID: 20156938
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
Ajamieh H; Farrell G; Wong HJ; Yu J; Chu E; Chen J; Teoh N
J Gastroenterol Hepatol; 2012 Aug; 27(8):1353-61. PubMed ID: 22432744
[TBL] [Abstract][Full Text] [Related]
12. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats.
Bataller R; Gäbele E; Parsons CJ; Morris T; Yang L; Schoonhoven R; Brenner DA; Rippe RA
Hepatology; 2005 May; 41(5):1046-55. PubMed ID: 15841463
[TBL] [Abstract][Full Text] [Related]
13. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
[TBL] [Abstract][Full Text] [Related]
14. Gingerol protects against experimental liver fibrosis in rats via suppression of pro-inflammatory and profibrogenic mediators.
Algandaby MM; El-Halawany AM; Abdallah HM; Alahdal AM; Nagy AA; Ashour OM; Abdel-Naim AB
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):419-28. PubMed ID: 26809353
[TBL] [Abstract][Full Text] [Related]
15. Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus.
Riad A; Du J; Stiehl S; Westermann D; Mohr Z; Sobirey M; Doehner W; Adams V; Pauschinger M; Schultheiss HP; Tschöpe C
Eur J Pharmacol; 2007 Aug; 569(3):204-11. PubMed ID: 17669395
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1.
Araújo FA; Rocha MA; Mendes JB; Andrade SP
Biomed Pharmacother; 2010 Jan; 64(1):29-34. PubMed ID: 19811885
[TBL] [Abstract][Full Text] [Related]
17. Docosahexaenoic acid attenuates carbon tetrachloride-induced hepatic fibrosis in rats.
He J; Bai K; Hong B; Zhang F; Zheng S
Int Immunopharmacol; 2017 Dec; 53():56-62. PubMed ID: 29035816
[TBL] [Abstract][Full Text] [Related]
18. Oxymatrine attenuates CCl4-induced hepatic fibrosis via modulation of TLR4-dependent inflammatory and TGF-β1 signaling pathways.
Zhao HW; Zhang ZF; Chai X; Li GQ; Cui HR; Wang HB; Meng YK; Liu HM; Wang JB; Li RS; Bai ZF; Xiao XH
Int Immunopharmacol; 2016 Jul; 36():249-255. PubMed ID: 27179304
[TBL] [Abstract][Full Text] [Related]
19. The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1-42 in the rat hippocampus in vivo.
Clarke RM; O'Connell F; Lyons A; Lynch MA
Neuropharmacology; 2007 Jan; 52(1):136-45. PubMed ID: 16920163
[TBL] [Abstract][Full Text] [Related]
20. Nicorandil and atorvastatin attenuate carbon tetrachloride - induced liver fibrosis in rats.
Abdel-Sattar AR; Abo-Saif AA; Aboyoussef AM
Immunopharmacol Immunotoxicol; 2020 Dec; 42(6):582-593. PubMed ID: 32988255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
